Cargando…
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers arising in lymphoid tissues that commonly effects both humans and dogs. Protein arginine methyltransferase 5 (PRMT5), an enzyme that catalyzes the symmetric di-methylation of arginine residues, is frequently overexpressed and dysre...
Autores principales: | Sloan, Shelby L., Renaldo, Kyle A., Long, Mackenzie, Chung, Ji-Hyun, Courtney, Lindsay E., Shilo, Konstantin, Youssef, Youssef, Schlotter, Sarah, Brown, Fiona, Klamer, Brett G., Zhang, Xiaoli, Yilmaz, Ayse S., Ozer, Hatice G., Valli, Victor E., Vaddi, Kris, Scherle, Peggy, Alinari, Lapo, Kisseberth, William C., Baiocchi, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121334/ https://www.ncbi.nlm.nih.gov/pubmed/33989303 http://dx.doi.org/10.1371/journal.pone.0250839 |
Ejemplares similares
-
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023) -
Discovery of Potent and Selective Covalent Protein
Arginine Methyltransferase 5 (PRMT5) Inhibitors
por: Lin, Hong, et al.
Publicado: (2019) -
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
por: Shailesh, Harshita, et al.
Publicado: (2018) -
Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells
por: Rasheed, Shayaan, et al.
Publicado: (2023) -
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
por: Hing, Zachary A., et al.
Publicado: (2023)